# A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

> **NCT04152382** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 30 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** LY3462817 - IV
- **DRUG:** LY3462817 - SC
- **DRUG:** Placebo - IV
- **DRUG:** Placebo - SC
- **DRUG:** LY3509754
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04152382
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-20
- **Primary completion:** 2022-02-09
- **Final completion:** 2022-02-09
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Terminated due to liver findings
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152382, "A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04152382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*